Shanghai Fosun Pharmaceutical (SHA:600196) said China's drug regulator accepted the drug registration application for subsidiary Suzhou Erye's heparin sodium injection, according to a filing with the Shanghai bourse.
The anticoagulant is intended for a wide range of uses, including preventing thrombosis, treating embolic complications, and supporting surgical and dialysis procedures.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments